Br J Clin Pharmacol 1996; **42**: 791–798

AUTHOR INDEX

(P = Proceedings)

AARTS M., GRUCHALLA R. & RIEDER M.J. Sulphonamide-specific haptens during sulphonamide therapy, 679P

ABDELMAWLA A.H., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Comparison of the effects of nadolol and bisoprolol on noradrenaline-evoked venoconstriction in man, 279P

ABELLA A., MESSAOUDI C., LAURENT D., MAROT D., CHALAS J., BREUX J., CLAISE C. & LINDENBAUM A. A method for simultaneous determination of plasma and erythrocyte antioxidant status. Evaluation of the antioxidant activity of vitamin E in healthy volunteers, 737

ADAMS D.A. *see* BOOBIS A.R.

ADAMS D.A. *see* CLIFFORD C.P.

AHMED A. *see* TURNER C.L.

AITKEN M. *see* WOOD N.D.

AL-MAHDAWI S. *see* NUNEZ D.J.R.

AL-TUBULY R. *see* WILKINS M.R.

ALLEN M.B. *see* MORICE A.H.

ALLEN M.J. *see* MUIRHEAD G.J.

ALLPORT J.R., DONNELLY L.E., KEFALAS P., LO G., NUNN A., YADOLLAHI-FARSANI M., RENDELL N.B., MURRAY S., TAYLOR G.W. & MacDERMONT J. A possible role for mono(ADP-ribosyl) transferase in the signalling pathway mediating neutrophil chemotaxis, 99

ALM C. *see* BOTTIGER Y.

ALMAWI W.Y. *see* HESS D.

ALVAN G. *see* BOTTIGER Y.

AMBROS R.J. *see* KLOKE H.J.

AMMI-SAID M. *see* DE PINIEUX G.

ANDREWS H. *see* DURSUN S.M.

ANDRIANI A. *see* MEGNIEN J.L.

ANGEBAUD P. *see* DEMOLIS J-L.

ANGEL A. *see* FROESE D.E.

ANUMBA D. *see* MAJMUDAR N.G.

ANUMBA D.O.C., ROBSON S.G. & FORD G.A. The role of nitric oxide in the modulation of vascular tone in normal pregnancy, 651P

ARMITAGE J.M. *see* KEECH A.C.

ARNAU A.P.M. *see* MONSO A.

ARONSON J.K. *see* SMITH C.C.

ARYA D.K. *see* SZABADI E.

ASCASO C. *see* GRAU J.J.

ASTBURY S. *see* YOGENDRAN L.

ASTIER A. *see* DE PINIEUX G.

ATKIN K. *see* O'SULLIVAN D.P.

ATKINSON F.M. *see* RANCE D.J.

AUDRAN M. *see* SOUILLARD A.

AUERNHAMMER C.J. *see* RIEPL R.L.

BACK D. *see* MERRY C.

BACK D.J. *see* EAGLING V.A.

BACK D.J. *see* HOGGARD P.G.

BACK D.J. *see* KEWN S.

BACK D.J. *see* SALES S.D.

BACK D.J. *see* VEAL G.J.

BAMFORD D. *see* NOTARIANNI L.J.

BANGS A. *see* O'SULLIVAN D.P.

BANI M. *see* BOTTIGER Y.

BARBAL F. *see* MONSO A.

BARBHAIYA R.H. *see* SHYU W.C.

BARBHAIYA R.H., BUCH A.B. & GREENE D.S. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan, 573

BARNES P.J. Pathophysiology of asthma, 3

BARNES P.J. *see* SMITH S.F.

BARRON W. *see* McCRINDLE J.L.

BARRY M. *see* MERRY C.

BARRY M.G. *see* HOGGARD P.G.

BARRY M.G. *see* KEWN S.

BARRY M.G. *see* VEAL G.J.

BASCI N.E., BOZKURT A., KORTUNA S., ISIMER A., SAYAL A. & KAYAALP S.O. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population, 771

BASSETTI M.A. *see* MARCIANI M.G.

BATEMAN D.N. *see* THOMAS A.H.L.

BATTY K.T. *see* DAVIS T.M.E.

BEERAHEE A., TAYLOR A.C., CITERONE D., DAVY M., FITZPATRICK K., LOPEZ-GIL A. & STOCCHI F. Steady-state pharmacokinetics of digoxin during repeat oral administration of ropinirole in parkinsonian patients, 668P

BEEVERS D.G. *see* MARSHALL H.J.

BEIER G. *see* RIEPL R.L.

BEJAMINOV A. *see* HARDER S.

BENET L.Z. *see* SAMBOL N.C.

BENHAMOU D. *see* MAZOIT J.X.

BENNETT P.M. *see* SMITH C.C.

BENNETT P.N. & NOTARIANNI L.J. Risk from drugs in breast milk: an analysis by relative dose, 673P

BERNARDI G. *see* MARCIANI M.G.

BERTILSSON L. *see* BOTTIGER Y.

BERTILSSON L. *see* MASIMIREMBWA C.

BESSER M. *see* BOULOUX P-M.

BHADRESA S. *see* GOODERHAM N.J.

BIKHAZI G.B. *see* FRYE R.F.

BILLARD V. *see* KNOBLER R.M.

BIRD I.A. *see* HESS D.

BIRKETT D.J. *see* TASSANEEYAKUL W.

BITSIOS P., SZABADI E. & BRADSHAW C.M. Comparison of the effects of psychological threat and clonidine on the kinetics of the pupillary light reflex in man, 269P

BLANCH J.L. *see* GRAU J.J.

BLIESATH H. *see* GUGLER R.

BLOOD P. *see* DONALDSON K.M.

BODE-BOGER S.M. *see* BOGER R.H.

BOGER R.H., BODE-BOGER S.M., KRAMME P., TSIKAS D., GUTZI F-M. & FROLICH J.C. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid, 721

BOOBIS A.R. *see* CLIFFORD C.P.

BOOBIS A.R. *see* GOODERHAM N.J.

BOOBIS A.R., EDWARDS R.J., ADAMS D.A. & DAVIES D.S. Dissecting the function of P450, 81

BOOKJANS G. *see* KIVISTO K.T.

BOTTIGER Y., DOSTERT D., STROLIN BENEDETTI M., BANI M., FIORENTINI F., CASATI M., POGGESTI I., ALM C., ALVAN G. & BERTILSSON L. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans, 707

BOULANGER C.M. *see* LONGMORE J.

BOULOUX P-M., CORSELLO S., BESSER M. & GROSSMAN A. The acute cardiovascular actions of intravenous thyrotrophin releasing hormone (TRH) in man are mediated by non-catecholamine mechanisms, 225

BOWMER C.J. *see* WANG Y.

BOYS R. *see* MAJMUDAR N.G.

BOZKURT A. *see* BASCI N.E.

BRADSHAW C.M. *see* ABDELMAWLA A.H.

BRADSHAW C.M. *see* BITSIOS P.

BRADSHAW C.M. *see* MORTLOCK S-A.

BRADSHAW C.M. *see* SZABADI E.

BRATT C. *see* GOODERHAM N.J.

BRECKENRIDGE A. A clinical pharmacologist's view of drug toxicity, 53

BRESSOLLE F. *see* SOUILLARD A.

BREUX J. *see* ABELLA A.

BREWER T.G. *see* TEJA-ISAVADHARM P.

BRITTON J. *see* HILL J.M.

BROD I. *see* GUGLER R.

BRODDE O-E. *see* BUSCHER R.

BROOKES L.G. *see* SAMBOL N.C.

BROOKS C. *see* WEEKES L.M.

BROWN M.J. *see* WANG T.

BROWN M.J. The causes of essential hypertension, 21

BUCH A.B. *see* BARBHAIYA R.H.

BURGGRAAF J., SCHOEMAKER H.C. & COHEN A.F. Assessment of changes in liver blood flow after food intake—

© 1996 Blackwell Science Ltd

comparison of ICG clearance and echo-Doppler, 499
BURKE J.G. *see* DURSUN S.M.
BURKE J.G. *see* PATEL J.K.M.
BURKE J.G. *see* SIMMS M.G.N.
BURLEW B.S. *see* SOWINSKI K.M.
BUSCHER R., SCHWIEBERT C., JAKEL S., GRABEN N., BRODDE O-E. & MICHEL M.C. Platelet adenylyl cyclase activity in uraemic patients, 269P

CALVERT R. *see* WOLFF K.
CAMPBELL J.H. *see* MORICE A.H.
CANFIELD C.J. *see* HUSSEIN Z.
CARGILL R.I. *see* KIELY D.G.
CASATI M. *see* BOTTIGER Y.
CERIMELE B.J. *see* MARDER P.
CHALAS J. *see* ABELLA A.
CHALMERS J. The treatment of hypertension, 37
CHAMPOUX N., DU SOUICH P., RAVAOARINORO M., PHANEUF D., LATOUR J. & CUSSON J.R. Single-dose pharmacokinetics of ampicillin and tobramycin administered by hyperdermoclysis in young and older healthy volunteers, 325
CHANAL J-L. *see* SOUILLARD A.
CHARIOT P. *see* DE PINIEUX G.
CHARLETT A. *see* DOBBS S.M.
CHIANG J. *see* SAMBOL N.C.
CHIRON C. *see* VAUZELLE-KERVROEDAN F.
CHOI K.L. *see* LAM K.S.L.
CHOONARA I., GILL A. & NUNN A. Drug toxicity and surveilance in children, 407
CHOY P.C. *see* FROESE D.E.
CHRISTIE M. *see* STARMER G.A.
CHRYSTYN H., LIPWORTH B.J. & CLARK D.J. Letter to the Editors: Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol, 257
CIOFANI G. *see* LAPENNA D.
CITERONE D. *see* BEERAHEE A.
CLAISE C. *see* ABELLA A.
CLARK D.J. & LIPWORTH B.J. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, 654P
CLARK D.J. *see* CHRYSTYN H.
CLARK D.J., CLARK R.A. & LIPWORTH B.J. Comparative systemic bioactivity of inhaled budesonide and fluticasone propionate in asthmatic children, 264P
CLARK R.A. *see* CLARK D.J.
CLEOPHAS T.J.M. Letter to the Editors: Crossover trials, a reply, 402
CLIFFORD C.P. *see* NUNEZ D.J.R.
CLIFFORD C.P., ADAMS D.A., MURRAY S., TAYLOR G.W., WILKINS M.R., BOOBIS A.R. & DAVIES D.S. Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice, 662P
COATES P. *see* DEMOLIS J-L.
COCKCROFT J.R. *see* GARDNER-MEDWIN J.M.
COCKCROFT J.R., GARDNER-MEDWIN J.M., MACDONALD I.A. & POWELL R.J. Reduced nitric oxide-dependent vasodilatation in primary Raynaud's phenomenon, 650P
COHEN A.F. *see* BURGGRAAF J.
COHEN A.F. *see* SCHOEMAKER R.C.
COHEN A.F. *see* VAN GERVEN J.M.A.
COLLINS G.G.S. *see* DEWHURST D.G.
COLLINS R. *see* KEECH A.C.
COOPER D.M. *see* JONES R.W.
CORSELLO S. *see* BOULOUX P-M.
COUTIE W. *see* LEE A.F.C.
COUTIE W.J. *see* KIELY D.G.
COX J., EDWARDS C., FULLERTON R., KESTEVEN P., WYNNE H. & KAMALI F. Temporal variations in clotting factor activity, 674P
CRABBE R. *see* SNOECK E.
CRAWFORD F.E. *see* MILLER A.J.
CROSBIE S.J. *see* GOODERHAM N.J.
CUCCURULLO F. *see* LAPENNA D.
CUCHI M.A. *see* GRAU J.J.
CUSSON J.R. *see* CHAMPOUX N.

d'ATHIS Ph. *see* VAUZELLE-KERVROEDAN F.
DANHOF M. *see* SNOECK E.
DANIELE F. *see* LAPENNA D.
DASGUPTA M. *see* SKEITH K.J.
DAVIES D.S. Preface, 1
DAVIES D.S. *see* BOOBIS A.R.
DAVIES D.S. *see* CLIFFORD C.P.
DAVIES D.S. *see* GOODERHAM N.J.
DAVIS I.M. *see* KOCH K.M.
DAVIS J.D., DIXON R., KHAN A.Z., TOON S., ROLAN P.E. & POSNER J. Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers, 246
DAVIS J.M. *see* KOCH K.M.
DAVIS T.M.E., DEMBO L.G., KAYE-EDDIE S.A., HEWITT B.J., HISLOP R.G. & BATTY K.T. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo controlled trial, 415
DAVY M. *see* BEERAHEE A.
DE GIOIA S. *see* LAPENNA D.
DE PINIEUX G., CHARIOT P., AMMI-SAID M., LOUARN F., LEJONC J.L., ASTIER A., JACOTOL B. & GHERARDI R. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio, 333
DEAN A.J. *see* STARMER G.A.
DELABAR U. *see* GLEITER C.H.
DELANTY N., REILLY M., PRATICO D., FITZGERALD D.J., LAWSON J.A. & FITZGERALD G.A. 8-Epi PGF 2α: specific analysis of an isoeicosanoid as an index of oxidant stress *in vivo*, 15
DEMBINSKI T.C. *see* FROESE D.E.
DEMBO L.G. *see* DAVIS T.M.E.
DEMOLIS J-L., ANGEBAUD P., GRANGE J-D., COATES P., FUNCK-BRENTANO C. & JAILLON P. Influence of liver cirrhosis on sertraline pharmacokinetics, 394
DESTA B. *see* LONGMORE J.
DEWHURST D.G., COLLINS G.G.S. & JOSHI P. The pharmacology of epilepsy: an interactive, computer-based tutorial program for undergraduate students, 679P
DEWLAND P.M. *see* MUIRHEAD G.J.
DINAN T.G. *see* EDWARDS J.G.
DIXON R. *see* DAVIS J.D.
DOBBS R.J. *see* DOBBS S.M.
DOBBS S.M., DOBBS R.J. & CHARLETT A. Editorial: Multi-centre trials: U-turns by bandwagons and the patient left by the wayside, 143
DOLLERY C. Clinical pharmacology: the future prospects for the discipline, 137
DONALDSON K.M., BLOOD P., PETERS G.R., WRIGHT C.E. & HARRY J.D. An evaluation of some cardiovascular effects of pramipexole in healthy volunteers and their antagonism by domperidone, 660P
DONNELLY L.E. *see* ALLPORT J.R.
DONNELLY L.E. *see* TAYLOR G.W.
DOSTERT D. *see* BOTTIGER Y.
DRAKE J. *see* MILLER A.J.
DU SOUICH P. *see* CHAMPOUX N.
DULAC O. *see* VAUZELLE-KERVROEDAN F.
DUMAS C. *see* VAUZELLE-KERVROEDAN F.
DUPONT A. *see* SNOECK E.
DURSUN S.M. *see* PATEL J.K.M.
DURSUN S.M. *see* SIMMS M.G.N.
DURSUN S.M., PATEL J.K.M., WALKER M., BURKE J.G. & REVELEY M.A. Effects of typical antipsychotic drugs (typ-APD)− and resperidone (RISP) on the quality of sleep in schizophrenia, 273P
DURSUN S.M., SZEMIS A., ANDREWS H., REVELEY M.A. & WHITAKER R.P. Effects of typical antipsychotic drugs (typ-APD) and clozapine (CPZ) on plasma 5-HT turnover and impulsivity in schizophrenia, 272P
DUTKA D. *see* NUNEZ D.J.R.
DUVALLET A. *see* SOUILLARD A.
DYKES C.W. Genes, disease and medicine, 683

EAGLES C.J., KENDALL M.J. & MAXWELL S. A comparison of the exercise metabolism effects of fluvastatin and bezafibrate: a placebo-controlled study in healthy normolipidaemic subjects, 281P
EAGLING V.A., TJIA J.F. & BACK D.J. Differential selectivity of cytochrome P450 inhibitors against four probe substrates in human and rat liver microsomes, 673P
EAVES C.J. *see* HUSSEIN Z.
ECCLES R. *see* FERGUSON E.A.

ECCLES R. *see* FREESTONE C.
ECKARDT K.U. *see* GLEITER C.H.
EDWARDS C. *see* COX J.
EDWARDS C. *see* WYNNE H.
EDWARDS I.G. Book review—Handbook of Drugs for Tropical Parasitic Infections (2nd edn) by Y.A. Abdi, L.L. Gustafsson, O. Ericsson & U. Hellegren, 405
EDWARDS J.G., DINAN T.G., WALLER D.G. & GREENTREE S.G. Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline, 491
EDWARDS R.J. *see* BOOBIS A.R.
EDWARDS R.J. *see* GOODERHAM N.J.
ELLIS S.W. *see* GHAHRAMANI P.
ESTAN L. *see* MARTINEZ-MIR I.
ESTAPE J. *see* GRAU J.J.

FEELEY M. *see* WOLFF K.
FERGUSON E.A. & ECCLES R. Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant, 657P
FERRER J.M. *see* MARTINEZ-MIR I.
FIORENTINI F. *see* BOTTIGER Y.
FIRVIDA J.L. *see* GRAU J.J.
FITZGERALD D.J. *see* DELANTY N.
FITZGERALD G.A. *see* DELANTY N.
FITZPATRICK K. *see* BEERAHEE A.
FLETCHER E. *see* THOMAS S.H.L.
FORD G.A. *see* ANUMBMA D.O.C.
FORD G.A. *see* MAJMUDAR N.G.
FORSLING M.L. *see* SAWYER A.
FOSTER R.W., ZOUGH N.A. & SMALL R.C. Bioassay of salmeterol from commercial formulations, 271P
FOX J. *see* JONES R.W.
FREESTONE C., ECCLES R., MORRIS S. & JAWAD M.S.M. Assessment of the antitussive efficacy of codeine using cough sound pressure levels as a means of measuring cough, 656P
FREESTONE S. *see* LI KAM WA T.C.
FREUNDENTHALER S. *see* GLEITER C.H.
FROELICH L.L. *see* MARDER P.
FROESE D.E., LI CHEN S-Y., DEMBINSKI T.C., HATCH G.M., MYMIN D., SHEN G., ANGEL A., KROEGER E.A., CHOY P.C. & MAN R.Y.K. Gender-related differences in oxidized low density lipoproteins, 662P
FROLICH J.C. *see* BOGER R.H.
FROMM M.F. *see* KIVISTO K.T.
FRYE R.F., MATZKE G.R., JALLAD N.S., WILHELM J.A. & BIKHAZI G.B. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene, 301
FULLER R.W. The asthma death problem revisited, 11
FULLERTON R. *see* COX J.
FUNCK-BRENTANO C. *see* DEMOLIS J-L.

GALLICANO K. & SAHAI J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans, 632
GARCIA RODRIGUEZ L.A., MANNINO S., WALLANDER M.A. & LINDBLOM B. A cohort study of the ocular safety of anti-ulcer drugs, 213
GARCIA-LOPEZ M. *see* MARTINEZ-MIR I.
GARDNER-MEDWIN J.M. *see* COCKCROFT J.R.
GARDNER-MEDWIN J.M., COCKCROFT J.R. & MACDONALD I.A. A greater contribution from nitric oxide to endothelium-dependent vasodilatation in women, 660P
GAREAU R. *see* SOUILLARD A.
GEORGE C.F. *see* SULLIVAN M.J.
GHAHRAMANI P., ELLIS S.W., LENNARD M.S., RAMSAY L.E. & TUCKER G.T. The identification of human cytochromes P450 mediating the *N*-demethylation of amitriptyline, 260P
GHERARDI R. *see* DE PINIEUX G.
GIBBONS S. *see* MERRY C.
GIGLI G.L. *see* MARCIANI M.G.
GILL A. *see* CHOONARA I.
GILL H.J., MAGGS J.L., MADDEN S., PIRMOHAMED M. & PARK B.K. The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole, 347
GILL H.J., MAGGS J.L., MADDEN S., PIRMOHAMED M. & PARK B.K. The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole in man, 270P
GLEITER C.H., FREUNDENTHALER S., DELABAR U., ECKARDT K.U., MUHLBAUER B., GUNDERT-REMY U. & OSSWALD H. Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine, 729
GNOSSPELIUS Y. *see* TAN K.S.
GODLEWSKI G. *see* NOTARIANNI L.J.
GOODERHAM N.J., MURRAY S., LYNCH A.M., EDWARDS R.J., YADOLLAHI-FARSANI M., BRATT C., RICH K.J., ZHAO K., MURRAY B.P., BHADRESA S., CROSBIE S.J., BOOBIS A.R. & DAVIES D.S. Heterocyclic amines: evaluation of their role in diet associated with human cancer, 91
GOODING A.E. *see* KOCH K.M.
GOODMAN A.M. *see* SAMBOL N.C.
GRABEN N. *see* BUSCHER R.
GRAHAME-SMITH D.G. *see* SMITH C.C.
GRANGE J-D. *see* DEMOLIS J-L.
GRAU J.J., ESTAPE J., CUCHI M.A., FIRVIDA J.L., BLANCH J.L. & ASCASO C. Calcium supplementation and ototoxicity in patients receiving cisplatin, 233
GREENE D.S. *see* BARBHAIYA R.H.
GREENTREE S.G. *see* EDWARDS J.G.
GRIESE E.U. *see* KIVISTO K.T.
GROSSMAN A. *see* BOULOUX P-M.
GROVE A. *see* TAN K.S.
GRUCHALLA R. *see* AARTS M.
GUGLER R., HARTMANN M., RUDI J., BROD I., HUBER R., STEINIJANS V.W., BLIESATH H., WURST W. & KLOTZ U. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man, 249
GUNDERT-REMY U. *see* GLEITER C.H.
GUTZI F-M. *see* BOGER R.H.

HAAGSMA C.J., RUSSEL F.G.M., VREE T.B., RIEL P.L.C.M. & VAN DE PUTTE L.B.A. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response, 195
HARDER S., THURMANN P.A., HELLSTERN A. & BEJAMINOV A. Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis, 443
HARRIS S. *see* WOOD N.D.
HARRISON P.I. *see* SMITH C.C.
HARRY J.D. *see* DONALDSON K.M.
HART C.A. *see* SALES S.D.
HARTIGAN-GO K. *see* THOMAS A.H.L.
HARTMANN M. *see* GUGLER R.
HASLER J. *see* MASIMIREMBWA C.
HATCH G.M. *see* FROESE D.E.
HAUER A.J. *see* KEECH A.C.
HAWORTH J. *see* JONES R.W.
HAY A.W.M. *see* WOLFF K.
HE N. *see* WAN J.
HEINING R. *see* WENSING G.
HELLER S.R. *see* ROSTAMI-HODJEGAN A.
HELLSTERN A. *see* HARDER S.
HERMAN R.J. & WILKINSON G.R. Disposition of diazepam in young and elderly subjects after acute and chronic dosing, 147
HESS D. & REIDER M.J. Inhibition of Th2 specific cytokine production by reactive metabolites, 655P
HESS D., BIRD I.A., ALMAWI W.Y. & RIEDER M.J. Synergistic inhibition of T cell proliferation by reactive drug metabolites, 656P
HEWITT B.J. *see* DAVIS T.M.E.
HEYKANTS J. *see* SNOECK E.
HILL J.M. & BRITTON J. Effect of intravenous magnesium sulphate on airway calibre and airway reactivity to histamine in asthmatic subjects, 629
HILL R.G. *see* LONGMORE J.
HINDMARCH I. *see* KERR J.S.
HIROKAWA K. Clinical pharmacologists and drug regulation—future perspective in Japan, 63
HISLOP R.G. *see* DAVIS T.M.E.
HOEDEMAKER H.G.J. *see* VAN GERVEN J.M.A.

HOGGARD P.G. *see* KEWN S.
HOGGARD P.G., BARRY M.G., KHOO S.H. & BACK D.J. Drug interactions with d4T phosphorylation *in vitro*, 278P
HORTH C.E. *see* MILLER A.J.
HOUSTON A.C. *see* MUIRHEAD G.J.
HOUSTON J.B. & ZOMORODI K. Diazepam-omeprazole inhibition interaction: an *in vitro* investigation using human liver microsomes, 157
HUBER R. *see* GUGLER R.
HUSSEIN Z., EAVES C.J., HUTCHINSON D.B. & CANFIELD C.J. Population pharmacokinetics of proguanil in patients with acute *P. falciparum* malaria after combined therapy with atovaquone, 589
HUTCHINGS A.D. & ROUTLEDGE P.A. A single sample saliva test to determine acetylator phenotype, 635
HUTCHINSON D.B. *see* HUSSEIN Z.
HUYSMANS F.T.M. *see* KLOKE H.J.

IKEDA Y. *see* KIMURA M.
INGELMAN-SUNDBERG M. *see* MASIMIREMBWA C.
IP T.P. *see* LAM K.S.L.
ISIMER A. *see* BASCI N.E.

JACKSON P.R. & YEO W.W. Letter to the Editors: Cross over trials, 401
JACOBS L-D. *see* VAN GERVEN J.M.A.
JACOTOL B. *see* DE PINIEUX G.
JACQMIN P. *see* SNOECK E.
JAILLON P. *see* DEMOLIS J-L.
JAKEL S. *see* BUSCHER R.
JALLAD N.S. *see* FRYE R.F.
JAMALI F. *see* SKEITH K.J.
JAMES G.C. *see* MUIRHEAD G.J.
JAMES G.C. *see* RANCE D.J.
JANG I.J., SHIN S.G., LEE K.H., YIM D.S., LEE M.S., KOO H.H. & SOHN D.R. Erythrocyte thiopurine methyltransferase activity in a Korean population, 638
JAWAD M.S.M. *see* FREESTONE C.
JEANNIN S. *see* MEGNIEN J.L.
JEFFERIES T.M. *see* NOTARIANNI L.J.
JOHNSON J.A. *see* SOWINSKI K.M.
JOHNSON N.R. *see* LI KAM WA T.C.
JOHNSTON N.R. *see* LI KAM WA T.C.
JONES R.W. *see* TURNER C.L.
JONES R.W., COOPER D.M., HAWORTH J., LANGFORD H. & FOX J. The effect of food on the absorption of galanthamine in healthy elderly volunteers, 671P
JONES T.E. & MORRIS R.G. Diltiazem does not always increase blood cyclosporin concentration, 642
JOSHI P. *see* DEWHURST D.G.

KAIKO R.F. *see* MANDEMA J.P.
KAMALI F. *see* COX J.
KAMALI F. *see* WYNNE H.
KAUMANN A.J. *see* WANG T.
KAYAALP S.O. *see* BASCI N.E.
KAYE-EDDIE S.A. *see* DAVIS T.M.E.
KEECH A.C., ARMITAGE J.M., WALLENDSZUS K.R., LAWSON A., HAUER A.J., PARISH S.E. & COLLINS R. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a larger randomized placebo-controlled study, 483
KEFALAS P. *see* ALLPORT J.R.
KELLY P. *see* WYNNE H.
KENDALL F.D. *see* O'SULLIVAN D.P.
KENDALL M.J. *see* EAGLES C.J.
KERR B.M. *see* KOCH K.M.
KERR J.S., POWELL J. & HINDMARCH I. The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance, 239
KESTEVEN P. *see* COX J.
KEWN S., HOGGARD P.G., BARRY M.G. & BACK D.J. 3TC (lamivudine) phosphorylation *in vitro*: no interaction with zidovudine, 279P
KHAN A.Z. *see* DAVIS J.D.
KHOO S.H. *see* HOGGARD P.G.
KHOO S.H. *see* VEAL G.J.
KIELY D.G., CARGILL R.I., COUTIE W.J. & LIPWORTH B.J. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale, 261P
KIELY D.G., CARGILL R.I. & LIPWORTH B.J. Effects of oxygen therapy on diastolic filling in hypoxaemic cor pulmonale, 276P
KIELY D.G., CARGILL R.I., STRUTHRS A.D. & LIPWORTH B.J. Endothelin-1 impairs systolic and diastolic myocardial function in man, 262P
KIELY D.G. *see* LEE A.F.C.
KIELY D.G., LEE A.F.C., STRUTHERS A.D. & LIPWORTH B.J. Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man, 263P
KIM R.B. & WILKINSON G.R. Letter to the Editors: CYP2E1 activity is not altered by influenza vaccination, 529
KIMURA M., UMEMURA K., IKEDA Y., KOSUGE K., MIZUNO A., NAKANOMYO H., OHASHI K. & NAKASHIMA M. Pharmacokinetics and pharmacodynamics of (±)-solatol in healthy male volunteers, 583
KITCHENER S. *see* WOOD N.D.
KIVISTO K.T., BOOKJANS G., FROMM M.F., GRIESE E.U., MUNZEL P. & KROEMER H.K. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue, 387
KLOKE H.J., AMBROS R.J., VAN HAMERSVELT H.W., WETZELS J.F.M., KOENE R.A.P. & HUYSMANS F.T.M. Pharmacokinetics and haemodynamic effects of the angiotensin converting enzyme inhibitor cilazapril in hypertensive patients with normal and impaired renal function, 615
KLOTZ U. *see* GUGLER R.
KNOBLER R.M., TRAUTINGER F., BILLARD V. & SHAFER S.L. Letter to the Editors: Parenteral administration of 8-methoxypsoralen, 404
KOCH K.M., DAVIS J.M., GOODING A.E. & YIN Y. Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate, 201
KOCH K.M., KERR B.M., GOODING A.E. & DAVIS I.M. Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate, 207
KOENE R.A.P. *see* KLOKE H.J.
KOO H.H. *see* JANG I.J.
KORTUNA S. *see* BASCI N.E.
KOSUGE K. *see* KIMURA M.
KRAMME P. *see* BOGER R.H.
KROEGER E.A. *see* FROESE D.E.
KROEMER H.K. *see* KIVISTO K.T.
KROGH C. *see* RIEDER M.J.
KUHLMANN J. *see* WENSING G.
KUMANA C.R. *see* LAM K.S.L.
KWONG F.C.N.K., QUINN P.A. & NG L.L. Characterisation of two distinct uptake mechanisms for vitamin C in human lymphoblasts, 281P
KYLE D.E. *see* TEJA-ISAVADHARM P.

LAFOLEY L. *see* RIEDER M.J.
LAM K.S.L., WAT M.S., CHOI K.L., IP T.P., PANG R.W.C. & KUMANA C.R. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus, 379
LANGE R. *see* SKEITH K.J.
LANGFORD H. *see* JONES R.W.
LANGLEY R.W. *see* ABDELMAWLA A.H.
LANGLEY R.W. *see* MORTLOCK S-A.
LANGLEY R.W. *see* SZABADI E.
LAPENNA D., DE GIOIA S., CIOFANI G., DANIELE F. & CUCCURULLO F. Captopril has no significant scavenging antioxidant activity in human plasma *in vitro* or *in vivo*, 451
LAPORTE J-R. *see* MONSO A.
LATOUR J. *see* CHAMPOUX N.
LAURENT D. *see* ABELLA A.
LAWSON A. *see* KEECH A.C.
LAWSON J.A. *see* DELANTY N.
LEE A.F.C. *see* KIELY D.G.
LEE A.F.C., KIELY D.G., COUTIE W. & STRUTHERS A.D. The renin response to frusemide in man is nitric oxide-dependent, 652P
LEE K.H. *see* JANG I.J.
LEE M.R. *see* LI KAM WA T.C.
LEE M.S. *see* JANG I.J.
LEES K.R. *see* MURRAY L.S.
LEHNERT P. *see* RIEPL R.L.
LEJONC J.L. *see* DE PINIEUX G.
LENNARD L., WELCH J. & LILLEYMAN J.S. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites, 525
LENNARD M.S. *see* GHAHRAMANI P.

LENNARD M.S. *see* ROWLAND K.
LEVENSON J. *see* MEGNIEN J.L.
LEWIS L.L. A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles, 179
LEWIS P. The clinical pharmacologist in drug discovery and development, 133
LI CHEN S-Y. *see* FROESE D.E.
LI KAM WA T.C., FREESTONE S., McCRINDLE J.L., SAMSON R.R., JOHNSTON N.R. & LEE M.R. Effects of frusemide on the urinary excretion of dopamine and 5-hydroxytryptamine in normal man, 522
LI KAM WA T.C., FREESTONE S. & LEE M.R. Renal metabolism and effects of the glutamyl derivative of L-DOPA and 5-hydroxytryptophan in man, 650P
LI KAM WA T.C., FREESTONE S., SAMSON R.R., JOHNSON N.R. & LEE M.R. γ-L-glutamyl-5-hydroxy-L-tryptophan, but not γ-L-glutamyl-L-tryptophan, causes sodium retention in normal man, 365
LI KAM WA T.C. *see* McCRINDLE J.L.
LILLEYMAN J.S. *see* LENNARD L.
LIM S. *see* SMITH S.F.
LIMA J.J. *see* SOWINSKI K.M.
LIN E.T. *see* SAMBOL N.C.
LINDBLOM B. *see* GARCIA RODRIGUEZ L.A.
LINDENBAUM A. *see* ABELLA A.
LIPWORTH B.J. Clinical pharmacology of β_3-adrenoceptors, 291
LIPWORTH B.J. Pharmacokinetics of inhaled drugs, 697
LIPWORTH B.J. *see* CHRYSTYN H.
LIPWORTH B.J. *see* CLARK D.J.
LIPWORTH B.J. *see* KIELY D.G.
LIPWORTH B.J. *see* TAN K.S.
LIU C.Y. *see* SAMBOL N.C.
LO G. *see* ALLPORT J.R.
LONG A. *see* WYNNE H.A.
LONGMORE J., BOULANGER C.M., DESTA B., HILL R.G., SCHOFIELD W.N. & TAYLOR A.A. 5-HT_{1D} receptor agonists and human coronary artery reactivity *in vitro*: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519, 431
LONGON A. *see* MILANI M.
LOPEZ-GIL A. *see* BEERAHEE A.
LOUARN F. *see* DE PINIEUX G.
LU Y-Q. *see* WAN J.
LUCAS R.A. *see* MARDER P.
LUXEMBURGER C. *see* TEJA-ISAVADHARM P.
LYNCH A.M. *see* GOODERHAM N.J.

MacDERMONT J. *see* ALLPORT J.R.
MACDONALD I.A. *see* COCKCROFT J.R.
MACDONALD I.A. *see* GARDNER-MEDWIN J.M.
MACFARLANE L.C. *see* TAN K.S.
MACINTYRE F. *see* RANCE D.J.
MacLEAN A. *see* TAN K.S.
MACONOCHIE J.G. *see* THOMAS S.H.L.
MADDEN S. *see* GILL H.J.
MADERNA M. *see* MILANI M.
MAGGS J.L. *see* GILL H.J.
MAJMUDAR N.G., ANUMBA D., ROBSON S.C., BOYS R. & FORD G.A. The role of nitric oxide in β_2-adrenoceptor-mediated vasodilation in forearm arterial vasculature, 652P
MAN R.Y.K. *see* FROESE D.E.
MANDEMA J.P., KAIKO R.F., OSHLACK N., REDER R.F. & STANSKI D.R. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone, 747
MANNINO S. *see* GARCIA RODRIGUEZ L.A.
MARCIANI M.G., SPANEDDA F., BASSETTI M.A., MASCHIO M., GIGLI G.L., MATTIA D. & BERNARDI G. Effects of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis, 621
MARDER P., SPAETHE S.M., FROELICH L.L., CERIMELE B.J., PETERSEN B.H., TANNER T. & LUCAS R.A. Inhibition of *ex vivo* neutrophil activation by oral LY293111, a novel leukotriene B_4 receptor antagonist, 457
MAROT D. *see* ABELLA A.
MARSHALL H.J. & BEEVERS D.G. α-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility, 507
MARTENSSON E. *see* THOMAS A.H.L.
MARTINEZ-MIR I., GARCIA-LOPEZ M., PALOP V., FERRER J.M., ESTAN L., RUBIO E. & MORALES-OLIVAS F.J. A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital, 319
MASCHIO M. *see* MARCIANI M.G.
MASCORD D.J. *see* STARMER G.A.
MASIMIREMBWA C., PERSSON I., BERTILSSON L., HASLER J. & INGELMAN-SUNDBERG M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity, 713
MASSIE J.D. *see* SOWINSKI K.M.
MATSUI D.M. *see* RIEDER M.J.
MATTIA D. *see* MARCIANI M.G.
MATTILA M.J. & VANAKOSKI J. Zolpidem, diazepam and zopiclone similarly impair human performance and memory, 664P
MATZKE G.R. *see* FRYE R.F.
MAXWELL S. *see* EAGLES C.J.
MAZOIT J.X., BENHAMOU D., VEILLETTE Y. & SAMII K. Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection, 242
McCLELLAND G.R. *see* WOOD N.D.
McCRINDLE J.L. *see* LI KAM T.C.
McCRINDLE J.L., LIKAM WA T.C., BARRON W. & PRESCOTT L.F. Effect of food on the absorption of frusemide and bumetamide in man, 743
McFARLANE L.C. *see* TAN K.S.
McKAY A.V.P. *see* PRICE J.S.
McMILLAN A-M. *see* PATEL J.K.M.
MEGNIEN J.L., SIMON A., ANDRIANI A., SEGOND P., JEANNIN S. & LEVENSON J. Cholesterol lowering therapy inhibits the low-flow mediated vasoconstriction of the brachial artery in hypercholesterolaemic subjects, 187
MENHEERE P.P.C.A. *see* SELS J.P.J.E.
MERRY C., BARRY M., GIBBONS S., MULCAHY F. & BACK D. Letter to the Editors: Improved tolerability of ritonavir derived from pharmacokinetic principles, 787
MESSAOUDI C. *see* ABELLA A.
MIALL-ALLEN V.M. *see* YOGENDRAN L.
MICHEL M.C. *see* BUSCHER R.
MILANI M., LONGON A. & MADERNA M. Effects of picotamide, an antiplatelet agent, on cardiovascular events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study, 782
MILLER A.J., SMITH K.J., DRAKE J., HORTH C.E. & CRAWFORD F.E. Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations, Oramorph SR and MST Continus, 645
MINERS J.O. *see* TASSANEEYAKUL W.
MIZUNO A. *see* KIMURA M.
MONSO A., RIUDEUBAS J., BARBAL F., LAPORTE J-R. & ARNAU A.P.M. A randomized double-blind, placebo-controlled trial comparing pethidine to metamizol for treatment of post-anaesthetic shivering, 307
MORALES-OLIVAS F.J. *see* MARTINEZ-MIR I.
MORICE A.H., PEAKE M.D., ALLEN M.B., CAMPBELL J.H. & PARRY-BILLINGS M. Evaluation of a novel salbutamol dry powder inhaler: clinical equivalence to a standard metered dose inhaler and in-use stability, 658P
MORRIS R.G. *see* JONES T.E.
MORRIS S. *see* FREESTONE C.
MORTLOCK S-A., LANGLEY R.W., BRADSHAW C.M. & SZABADI E. Effect of locally applied prazosin on the kinetics of the pupillary light reflex, 236
MUHLBAUER B. *see* GLEITER C.H.
MUIR K.W. Thrombolysis for stroke: pushed out of the window?, 681
MUIRHEAD G.J., ALLEN M.J., JAMES G.C., PEARSON J., RANCE D.J., HOUSTON A.C. & DEWLAND P.M. Pharmacokinetics of sildenafil (VIAGRA), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers, 268P
MULCAHY F. *see* MERRY C.
MULLEN P.W. Effects of weighting (and formulation) on the occurrence of anomalous rate constant estimates observed when fitting the Bateman equation to concentration-time data, 669P

MUNZEL P. *see* KIVISTO K.T.
MURPHEY R. *see* NOTARIANNI L.J.
MURRAY B.P. *see* GOODERHAM N.J.
MURRAY L.S., SQUIRE I.B., LEES K.R. & REID J.L. Assessment of factors determining blood pressure response to ACE inhibition in patients with congestive heart failure, 280P
MURRAY S. *see* ALLPORT J.R.
MURRAY S. *see* CLIFFORD C.P.
MURRAY S. *see* GOODERHAM N.J.
MURRAY S. *see* TAYLOR G.W.
MYMIN D. *see* FROESE D.E.

NAKANOMYO H. *see* KIMURA M.
NAKASHIMA M. *see* KIMURA M.
NAUTA J.J.P. *see* SELS J.P.J.E.
NEEDHAM C.A. *see* O'SULLIVAN D.P.
NEUVONEN P.J. *see* VARHE A.
NEWBURY C. *see* NOTARIANNI L.J.
NG L.L. *see* KWONG F.C.N.K.
NIEUWENHUIJZEN KRUSEMAN A.C. *see* SELS J.P.J.E.
NOSTEN F. *see* TEJA-ISAVADHARM P.
NOTARIANNI L.J. *see* BENNETT P.N.
NOTARIANNI L.J. *see* TURNER C.L.
NOTARIANNI L.J., JEFFERIES T.M., PATEL M., NEWBURY C., GODLEWSKI G. & BAMFORD D. Seminal fluid: a vehicle for carcinogenic activity, 678P
NOTARIANNI L.J., MURPHEY R. & WEST S.J. Detection of drug abuse in pregnancy using Guthrie cards, 677P
NUNEZ D.J.R., CLIFFORD C.P., AL-MAHDAWI S. & DUTKA D. Hypertensive cardiac hypertrophy—is genetic variance the missing link?, 107
NUNN A. *see* ALLPORT J.R.
NUNN A. *see* CHOONARA I.
NYBERG G. *see* THOMAS A.H.L.

O'CONNELL M.T., TISON F., QUINN N.P. & PATSALOS P.N. Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease, 765
O'CONNOR B.J. *see* SMITH S.F.
O'SULLIVAN D.P., NEEDHAM C.A., BANGS A., ATKIN K. & KENDALL F.D. Postmarketing surveillance of oral terbinafine in the UK: a report of a large cohort study, 559
OHASHI K. *see* KIMURA M.
OLIVE G. *see* VAUZELLE-KERVROEDAN F.
OLKKOLA K.T. *see* VARHE A.
OSHLACK N. *see* MANDEMA J.P.
OSSWALD H. *see* GLEITER C.H.
OTTERVANGER J.P. *see* STRICKER B.H. Ch.
OUWERSLOOT-VAN DER MEIJ M.J. *see* VAN GERVEN J.M.A.
PALOP V. *see* MARTINEZ-MIR I.
PANG R.W.C. *see* LAM K.S.L.
PARISH S.E. *see* KEECH A.C.
PARK B.K. *see* GILL H.J.
PARRY-BILLINGS M. *see* MORICE A.H.
PASS M.C. *see* TASSANEEYAKUL W.
PATEL J.K.M. *see* DURSUN S.M.
PATEL J.K.M. *see* SIMMS M.G.N.
PATEL J.K.M., McMILLAN A-M., BURKE J.G., REVELEY M.A. & DURSUN S.M. Comparison of side-effect profile, resource utilisation and pharmacoeconomics of sulpiride (SUL) and chlorpromazine (CPZ) in schizophrenia, 271P
PATEL J.K.M., MCMILLAN A-M., DURSUN S.M., REVELEY M.A. & BURKE J.G. Comparative investigation of psychopathology and quality of life during chlorpromazine (CPZ) and sulpiride (SUL) treatment in schizophrenia: a longitudinal study, 665P
PATEL M. *see* NOTARIANNI L.J.
PATSALOS P.N. *see* O'CONNELL M.T.
PEACEY S.R. *see* ROSTAMI-HODJEGAN A.
PEAKE M.D. *see* MORICE A.H.
PEARCE H.M. *see* SMITH C.C.
PEARSON J. *see* MUIRHEAD G.J.
PEGGINS J.O. *see* TEJA-ISAVADHARM P.
PERSSON I. *see* MASIMIREMBWA C.
PERUCCA E. The new generation of antiepileptic drugs: advantages and disadvantages, 531
PETERS G.R. *see* DONALDSON K.M.
PETERSEN B.H. *see* MARDER P.
PHANEUF D. *see* CHAMPOUX N.
PIRMOHAMED M. *see* GILL H.J.
POGGESTI I. *see* BOTTIGER Y.
PONS G. *see* VAUZELLE-KERVROEDAN F.
POSNER J. *see* DAVIS J.D.
POWELL J. *see* KERR J.S.
POWELL R.J. *see* COCKCROFT J.R.
PRATICO D. *see* DELANTY N.
PRESCOTT L.F. *see* McCRINDLE J.L.
PRICE J.S., WALLER P.C., WOOD S.M. & McKAY A.V.P. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal 757

QUINN N.P. *see* O'CONNELL M.T.
QUINN P.A. *see* KWONG F.C.N.K.

RAMSAY L.E. *see* GHAHRAMANI P.
RANCE D.J. *see* MUIRHEAD G.J.
RANCE D.J., ATKINSON F.M., JAMES G.C., MACINTYRE F., WALKER D.K., WASTALL P. & SMITH D.A. The pharmacokinetics of sildenafil after single intravenous and oral doses to mouse, rat and dog, 267P
RAVAOARINORO M. *see* CHAMPOUX N.
RAWLINS M.D. The clinical pharmacologist in drug regulation: a European perspective, 59
REDER R.F. *see* MANDEMA J.P.
REICHARDT B. *see* RIEPL R.L.
REID J.L. New therapeutic agents for hypertension, 37
REID J.L. *see* MURRAY L.S.
REIDER M.J. *see* HESS D.
REILLY M. *see* DELANTY N.
REINTS A. *see* VAN GERVEN J.M.A.
RENDELL N.B. *see* ALLPORT J.R.
RENDELL N.B. *see* TAYLOR G.W.
REVELEY M.A. *see* DURSUN S.M.
REVELEY M.A. *see* PATEL J.K.M.
REVELEY M.A. *see* SIMMS M.G.N.
REY E. *see* VAUZELLE-KERVROEDAN F.
REYNOLDS D.J.M. *see* SMITH C.C.
RICH K.J. *see* GOODERHAM N.J.
RIEDER M.J. *see* AARTS M.
RIEDER M.J. *see* HESS D.
RIEDER M.J., MATSUI D.M., LAFOLEY L., SPINO M. & KROGH C. Modification of product monographs for paediatrics, 653P
RIEL P.L.C.M. *see* HAAGSMA C.J.
RIEPL R.L., REICHARDT B., AUERNHAMMER C.J., BEIER G., SCHOPOHL J., STALLA G.K. & LEHNERT P. Suppression of vagus-mediated pancreatic polypeptide release by μ-opiate receptor agonist loperamide in man, 371
RIUDEUBAS J. *see* MONSO A.
ROBSON S.C. *see* MAJMUDAR N.G.
ROBSON S.C. *see* ANUMBA D.O.C.
ROLAN P.E. *see* DAVIS J.D.
ROLAN P.E. *see* VAN F.
ROSTAMI-HODGSON A. *see* WOLFF K.
ROSTAMI-HODJEGAN A., PEACEY S.R., HELLER S.R. & TUCKER G.T. A pharmacokinetic-pharmacodynamic model to explain the biphasic insulinergic effect of tolbutamide and the suppressive role of lowering blood glucose on this effect, 675P
ROUTLEDGE P.A. *see* HUTCHINGS A.D.
ROWLAND K., WYNNE ELLIS S., LENNARD M.S. & TUCKER G.T. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes, 390
RUBIO E. *see* MARTINEZ-MIR I.
RUDI J. *see* GUGLER R.
RUSSEL F.G.M. *see* HAAGSMA C.J.

SAHAI J. *see* GALLICANO K.
SALES S.D., VEAL G.J., HART C.A. & BACK D.J. Zidovudine (ZDV) cytotoxicity *in vitro* linked to intracellular ZDV-monophosphate concentrations, 671P
SAMBOL N.C., BROOKES L.G., CHIANG J., GOODMAN A.M., LIN E.T., LIU C.Y. & BENET L.Z. Food intake and dosage level, but not tablet *vs* solution dosage form, affect the absorption of metformin HCl in man, 510
SAMII K. *see* MAZOIT J.X.
SAMSON R.R. *see* LI KAM WA T.C.
SANTONI-RUGIU E. *see* THORGEIRSSON S.S.
SAWYER A., SHARMA S., WILLIAMS A. & FORSLING M.L. The effect of melatonin on basal vasopressin release in man, 678P
SAYAL A. *see* BASCI N.E.

SCHOEMAKER H.C. *see* BURGGRAAF J.
SCHOEMAKER R.C. & COHEN A.F. Estimating impossible curves using NONMEM, 283
SCHOEMAKER R.C. *see* VAN GERVEN J.M.A.
SCHOFIELD W.N. *see* LONGMORE J.
SCHOPOHL J. *see* RIEPL R.L.
SCHWIEBERT C. *see* BUSCHER R.
SEGOND P. *see* MEGNIEN J.L.
SELS J.P.J.E., NAUTA J.J.P., MENHEERE P.P.C.A., WOLFFENBUTTEL B.H.R. & NIEUWENHUIJZEN KRUSEMAN A.C. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers, 503
SHAFER S.L. *see* KNOBLER R.M.
SHARMA S. *see* SAWYER A.
SHARP S. *see* WOOD N.D.
SHEN G. *see* FROESE D.E.
SHIN S.G. *see* JANG I.J.
SHIRES S. *see* WOLFF K.
SHYU W.C. & BARBHAIYA R.H. Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine, 513
SIMMS M.G.N., PATEL J.K.M., BURKE J.G., REVELEY M.A. & DURSUN S.M. Effects of typical and atypical antipsychotic drug treatments on prefrontal-temporal-cortical network function in schizophrenia as assessed by 'COWA', 665P
SIMMS M.G.N., PATEL J.K.M., BURKE J.G., REVELEY M.A. & DURSUN S.M. The effects of typical and atypical antipsychotic drug treatments on the Stroop Colour Word Interference Test in schizophrenia, 274P
SIMMS M.G.N., PATEL J.K.M., BURKE J.G., REVELEY M.A. & DURSUN S.M. The effects of typical and atypical antipsychotic drug treatments on the Wisconsin card sorting test in schizophrenia, 275P
SIMON A. *see* MEGNIEN J.L.
SKEITH K.J., DASGUPTA M., LANGE R. & JAMALI F. The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen, 163
SMALL R.C. *see* FOSTER R.W.
SMITH C.C., BENNETT P.M., PEARCE H.M., HARRISON P.I., REYNOLDS D.J.M., ARONSON J.K. & GRAHAME-SMITH D.G. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines, 423
SMITH D.A. *see* RANCE D.J.
SMITH J. *see* YOGENDRAN L.
SMITH K.J. *see* MILLER A.J.
SMITH S.F., BARNES P.J., O'CONNOR B.J. & LIM S. Evidence for secretion of lipocortin 1 into the upper and central airways of human subjects, 658P
SNOECK E., JACQMIN P., VAN PEER A., DANHOF M., VER DONCK K., VAN BELLE H., WOESTENBORGHS R., CRABBE R., VAN GOOL R., DUPONT A. & HEYKANTS J. The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine, 605
SOHN D.R. *see* JANG I.J.
SOUILLARD A., AUDRAN M., BRESSOLLE F., GAREAU R., DUVALLET A. & CHANAL J-L. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control 335
SOWINSKI K.M., LIMA J.J., BURLEW B.S., MASSIE J.D. & JOHNSON J.A. Racial differences in propranolol enantiomers kinetics following simultaneous i.v. and oral administration, 339
SPAETHE S.M. *see* MARDER P.
SPANEDDA F. *see* MARCIANI M.G.
SPINO M. *see* RIEDER M.J.
SQUIRE I.B. *see* MURRAY L.S.
STALLA G.K. *see* RIEPL R.L.
STANSKI D.R. *see* MANDEMA J.P.
STARMER G.A., DEAN A.J., CHRISTIE M. & MASCORD D.J. The effects of pseudoephedrine and ephedrine on the development of fatigue in a prolonged driving-related task, 666P
STEINIJANS V.W. *see* GUGLER R.
STOCCHI F. *see* BEERAHEE A.
STRICKER B.H. Ch., VAN RIEMSDIJK M.M., STURKENBOOM M.C.J.M. & OTTERVANGER J.P. Taste loss to terbinafine: a case-control study of potential risk factors, 313
STROLIN BENEDETTI M. *see* BOTTIGER Y.
STRUTHERS A.D. *see* KIELY D.G.
STRUTHERS A.D. *see* LEE A.F.C.
STURKENBOOM M.C.J.M. *see* STRICKER B.H. Ch.
SULLIVAN M.J. & GEORGE C.F. Medicine taking in Southampton: a second look, 567
SYMONDS H.W. *see* WANG Y.
SZABADI E. *see* ABDELMAWLA A.H.
SZABADI E. *see* BITSIOS P.
SZABADI E. *see* MORTLOCK S-A.
SZABADI E., ARYA D.K., LANGLEY R.W. & BRADSHAW C.M. Comparison of the effects of thermal stress and clonidine on automatic functions in man, 260P
SZEMIS A. *see* DURSUN S.M.

TAN K.S., GROVE A., MacLEAN A., GNOSSPELIUS Y. & LIPWORTH B.J. Systemic corticosteroid rapidly reverses formoterol-induced tachyphylaxis in asthmatic patients, 265P
TAN K.S., MacFARLANE L.C. & LIPWORTH B.J. Effects of prednisolone and fluticasone on lymphocyte β_2-adrenoceptors in asthmatic patients, 659P
TAN K.S., McFARLANE L.C. & LIPWORTH B.J. Low dose prednisolone protects against *in vivo* systemic β_2-adrenoceptor subsensitivity induced by formoterol, 654P
TAN K.S., McFARLANE L.C. & LIPWORTH B.J. The combined oral contraceptive abolishes cyclical changes in airway reactivity in female asthmatics, 264P
TANNER T. *see* MARDER P.
TASSANEEYAKUL W., BIRKETT D.J., PASS M.C. & MINERS J.O. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity *in vivo*, 777
TAYLOR A.A. *see* LONGMORE J.
TAYLOR A.C. *see* BEERAHEE A.
TAYLOR G.W. *see* ALLPORT J.R.
TAYLOR G.W. *see* CLIFFORD C.P.
TAYLOR G.W., DONNELLY L.E., MURRAY S. & RENDELL N.B. Excursions in biomedical mass spectrometry, 119
TEJA-ISAVADHARM P., NOSTEN F., KYLE D.E., LUXEMBURGER C., TER KUILE F., PEGGINS J.O., BREWER T.G. & WHITE N.J. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay, 599
TEMPLE R.J. The clinical pharmacologist in drug regulation: the US perspective 73
TER KUILE F. *see* TEJA-ISAVADHARM P.
THOMAS A.H.L., HARTIGAN-GO K., NYBERG G., MARTENSSON E. & BATEMAN D.N. Concentration-related cardiovascular and electrocardiographic effects of thioridazine, 265P
THOMAS M. *see* THOMAS S.H.L.
THOMAS S.H.L. & BATEMAN D.N. Epidemiology of poisoning presenting to hospitals in the north east of England, 266P
THOMAS S.H.L., THOMAS M., MACONOCHIE J.G. & FLETCHER E. Letter to the Editors: Drug-induced QT interval prolongation, 399
THORGEIRSSON S.S. & SANTONI-RUGIU E. Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis, 43
THURMANN P.A. *see* HARDER S.
TISON F. *see* O'CONNELL M.T.
TJIA J.F. *see* EAGLING V.A.
TOON S. *see* DAVIS J.D.
TRAUTINGER F. *see* KNOBLER R.M.
TSIKAS D. *see* BOGER R.H.
TUCKER G.T. *see* GHAHRAMANI P.
TUCKER G.T. *see* ROSTAMI-HODJEGAN A.

TUCKER G.T. *see* ROWLAND K.
TUCKER G.T. *see* WOLFF K.
TURNER C.L., AHMED A., JONES R.W. & NOTARIANNI L.J. Plasma antioxidant activity: variation with age, 661P

UMEMURA K. *see* KIMURA M.

VAN BELLE H. *see* SNOECK E.
VAN DE PUTTE L.B.A. *see* HAAGSMA C.J.
VAN F. & ROLAN P.E. The utility of the cold pain test to measure analgesia from intravenous morphine, 663P
VAN GERVEN J.M.A., SCHOEMAKER R.C., JACOBS L-D., REINTS A., OUWERSLOOT-VAN DER MEIJ M.J., HOEDEMAKER H.G.J. & COHEN A.F. Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary, 475
VAN GOOL R. *see* SNOECK E.
VAN HAMERSVELT H.W. *see* KLOKE H.J.
VAN PEER A. *see* SNOECK E.
VAN RIEMSDIJK M.M. *see* STRICKER B.H. Ch.
VANAKOSKI J. *see* MATTILA M.J.
VARHE A., OLKKOLA K.T. & NEUVONEN P.J. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction, 465
VAUZELLE-KERVROEDAN F., REY E., PONS G., d'ATHIS Ph., CHIRON C., DULAC O., DUMAS C. & OLIVE G. Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures, 779
VEAL G.J. *see* SALES S.D.
VEAL G.J., BARRY M.G., KHOO S.H. & BACK D.J. Activation of nucleoside analogue drugs used in combination in the MRC Quattro trial, 672P
VEILLETTE Y. *see* MAZOIT J.X.
VER DONCK K. *see* SNOECK E.
VREE T.B. *see* HAAGSMA C.J.

WALKER D.K. *see* RANCE D.J.
WALKER M. *see* DURSUN S.M.
WALLANDER M.A. *see* GARCIA RODRIGUEZ L.A.
WALLENDSZUS K.R. *see* KEECH A.C.
WALLER D.G. *see* EDWARDS J.G.
WALLER P.C. *see* PRICE J.S.
WAN J., XIA H., HE N., LU Y-Q. & ZHOU H-H. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype, 471
WANG T., KAUMANN A.J. & BROWN M.J. (-)-Timolol is a more potent antagonist of the positive inotropic effects of (-)-adrenaline than of those of (-)noradrenaline in human atrium, 217
WANG Y., SYMONDS H.W. & BOWMER C.J. N4-hydroxylation of sulphamethazine by mouse hepatic microsomes, 266P
WASTALL P. *see* RANCE D.J.
WAT M.S. *see* LAM K.S.L.
WEEKES L.M. & BROOKS C. Drug and Therapeutics Committees in Australia: expected and actual performance, 551
WELCH J. *see* LENNARD L.
WENSING G., HEINING R. & KUHLMANN J. Pharmacodynamics and pharmacokinetics of BAY × 7195 aerosol, a new and selective receptor antagonist of cysteinyl-leukotrienes, in normal volunteers, 171
WEST S.J. *see* NOTARIANNI L.J.
WETZELS J.F.M. *see* KLOKE H.J.
WHITAKER R.P. *see* DURSUN S.M.
WHITE N.J. *see* TEJA-ISAVADHARM P.
WILHELM J.A. *see* FRYE R.F.
WILKINS M.R. *see* CLIFFORD C.P.
WILKINS M.R., ZHAO L. & AL-TUBULY R. The regulation of pulmonary vascular tone, 127
WILKINSON G.R. *see* HERMAN R.J.
WILKINSON G.R. *see* KIM R.B.
WILLIAMS A. *see* SAWYER A.
WINSTANLEY P. Mefloquine: the benefits outweigh the risks, 411
WOESTENBORGHS R. *see* SNOECK E.
WOLFF K., HAY A.W.M., SHIRES S., FEELEY M., CALVERT R., ROSTAMI-HODGSON A. & TUCKER G.T. Single-dose pharmacokinetics of methadone in healthy subjects, 670P
WOLFFENBUTTEL B.H.R. *see* SELS J.P.J.E.
WOOD N.D., AITKEN M., HARRIS S., KITCHENER S., MCCLELLAND G.R. & SHARP S. The tolerability and pharmacokinetics of the cartilage protective agent (uco32-3555) in healthy male volunteers, 676P
WOOD S.M. *see* PRICE J.S.
WRIGHT C.E. *see* DONALDSON K.M.
WURST W. *see* GUGLER R.
WYNNE ELLIS S. *see* ROWLAND K.
WYNNE H. *see* COX J.
WYNNE H., KAMALI F., LONG A., EDWARDS C. & KELLY P. Confirmation of an inverse relationship between warfarin dosage and age: a retrospective longitudinal analysis, 675P
WYNNE H.A. & LONG A. Patient awareness of the adverse effects of non-steroidal anti-flammatory drugs (NSAIDs), 253

XIA H. *see* WAN J.
XIE H-G. *see* XU Z-H.
XU Z-H., XIE H-G. & ZHOU H-H. *In vivo* inhibition of CYP2C19 but not CYP2D6 by fluvoxamine, 518

YADOLLAHI-FARSANI M. *see* ALLPORT J.R.
YADOLLAHI-FARSANI M. *see* GOODERHAM N.J.
YEO W.W. *see* JACKSON P.R.
YIM D.S. *see* JANG I.J.
YIN Y. *see* KOCH K.M.
YOGENDRAN L., SMITH J., ASTBURY S. & MIALL-ALLEN V.M. Reproducibility of forearm blood flow under basal conditions and during local infusion of angiotensin II and bradykinin using strain gauge plethysmography, 277P

ZHAO K. *see* GOODERHAM N.J.
ZHAO L. *see* WILKINS M.R.
ZHOU H-H. *see* WAN J.
ZHOU H-H. *see* XU Z-H.
ZOMORODI K. *see* HOUSTON J.B.
ZOUGH N.A. *see* FOSTER R.W.

Br J Clin Pharmacol 1996; **42**: 799–801

SUBJECT INDEX

This index was compiled from the keywords

(P = Proceedings)

α-adrenoceptor blocking drugs, 507
α-glucosidase inhibitors, 503
ACE inhibition, 280P
ADP-ribosylation, 119
Absorption, 743
Acetylator phenotype, 635
Acetylcholinesterase inhibitor, 671P
Actin polymerization, 99
Acylglucuronide enantiomers, 163
Adenosine, 729
Adenosine breakdown inhibition, 605
Adenylyl cyclase, 269P
Adrenal suppression, 654P
Adrenaline, 217
Adrenoceptor blockade, 225
Adverse drug reactions, 53, 319, 423
Adverse effects, 253, 567
African population, 713
Age, 661P, 675P
Ageing, 147
Alcohol, 239, 471
Alzheimer's disease, 671P
Ambient temperature, 236
Amitriptyline, 239, 491, 260P
Amodiaquine, 53
Analgesia, 663P
Angiotensin II, 277P
Angiotensin II receptor blockade, 261P
Angiotensin converting enzyme inhibitors, 721
Angiotensin receptor antagonists, 37
Angiotensinogen, 21
Anti-ulcer drugs, 213
Antibiotics, 325
Antibodies, 81
Antidepressants, 239
Antiepileptic drugs, 531
Antimycotic, 3123
Antioxidant, 451, 737
Antioxidant activity, 661P
Antiplatelet drugs, 782
Antipsychotic, 274P, 275P
Antitussive efficacy, 656P
Artemether, 599
Aspergillus fumigatus, 119
Aspirin, 15
Asthma, 3, 26P, 264, 629, 654P, 659P
Asthma death, 11
Athletes, 355
Atovaquone, 246
Atropine, 371
Autoinduction, 443
Autonomic function, 260P

β-adrenoceptor agonists, 11
β_1-and β_2-adrenoceptors, 217
β_2-adrenoceptor, 652P
β_2-adrenoceptor subsensitivity, 654P
β_2-adrenoceptors, 659P
β_3-adrenoceptors, 291
Bantu, 713
Bateman equation, 669P
Bethanachol, 371
Bezafibrate, 281P
Bioassay, 271P
Bioavailability, 91, 599
Bismuth, 201, 207
Bisoprolol, 279P
Blacks, 339
Blood glucose, 675P
Blood pressure, 225, 280P
Blood velocity, 187
Book review, 405
Bradykinin, 277P, 721
Breast milk, 673P
Bronchial challenge, 171
Bronchial reactivity, 629
Budesonide, 264P, 654P
Bumetanide, 743
Butorphanol, 513

CFCs, 11
CYP1A2, 91, 390
CYP2C19, 157, 518
CYP2D6, 390, 518, 707
CYP2E1, 529
CYP3A, 157, 387
Calcium, 233
Calcium antagonists, 29
Captopril, 451
Carbamazepine, 53
Carcinogenesis, 43
Carcinogenic activity, 678P
Carcinogenicity, 91
Cartilage protective agent, 676P
Ceruletide, 371
Chemotaxis, 99
Childhood leukaemia, 525
Children, 264P, 407
Chinese, 471
Chlorofluorocarbon, 257
Chlorpromazine, 272P, 655P
Chlorzoxazone, 673P
Cholinergic system, 371
Chronic dosing, 147
Cilazapril, 615
Cimetidine, 513
Ciprofloxacin, 632
Circadian rhythm, 674P
Cirrhosis, 443
Cisplatin, 233
Clinical pharmacology, 59, 73, 133, 137
Clinical study, 195
Clinical trials, 63, 475
Clonidine, 242, 260P, 269P
Clotting factor, 674P
Clozapine, 272P
Codeine, 656P
Cognitive function, 239
Cold pain test, 663P
Combination, 195
Combination therapy, 29
Committee on Safety of Medicines, 423
Common cold, 657P
Compliance, 525
Computer-based tutorial program, 679P
Computerized EEG, 621
Concentration-time data, 669P
Congestive heart failure, 280P
Consecutive cycles, 179
Controlled release, 747
Coronary vasoconstriction, 431
Corticosteroids, 265P
Cortisol, 667P
Cough sound pressure, 656P
Creatinine clearance, 729
Cross over trials, 401, 402
Cyclic GMP, 721
Cyclooxygenase, 15
Cyclosporin, 642
Cytochrome P-450, 81, 260P, 387, 673P, 774
Cytochrome P4502D6, 573
Cytokine production, 655P

DDAVP, 379
Debrisoquine, 707, 713
Depression, 491
Desmethyldiazepam, 471
DiMeIQx, 91
Diabetes insipidus, 379
Diazepam, 147, 157, 249, 664P
Diazepam metabolism, 471
Digoxin, 668P
Dihydroartemesin, 599
Diltiazem, 642
Dipyridamole, 729
Discipline of Clinical Pharmacology and Therapeutics, 143
Diuretics, 29
Domperidone, 660P
Dopamine, 522
Dopamine D_2-receptor agonist, 660P
Dosage form, 510
Dose dependent, 465
Dose-proportionality, 510
Draflazine, 605
Drug abuse, 677P
Drug development, 133, 683
Drug discovery, 133
Drug interactions, 157, 246
Drug metabolism, 81, 339, 713
Drug monitoring, 765
Drug regulation, 59
Drug regulation in Japan, 63
Drug therapy, 29
Dry powder inhaler, 658P

ELSI, 684
Echo-Doppler, 499
Efficacy, 491
Elderly, 301, 325
Electrocardiography, 491

© 1996 Blackwell Science Ltd

Electronic diaries, 465
Electrospray, 119
Enantiomers, 779
Endocrine, 261P
Endothelin-1, 262P
Endothelium, 721
Eosinophils, 3
Ephedrine, 665P
Epidemiology, 11, 266P
Epidural anaesthesia, 242
Epilepsy, 621, 679P
Epithelial cells, 3
8-epi $PGF_{2\alpha}$, 15
Erythropoetin, 729
Essential hypertension, 21

Fatigue, 665P
Felbamate, 531
Fibrates, 333
Flow cytometry, 457
Flow meter, 187
Fluconazole, 270P, 347, 465
Fluoxetine, 757
Fluticasone, 264P, 654P, 659P
Fluvastatin, 281P
Fluvoxamine, 518, 757
Food, 268P, 645, 671P, 743
Food interaction, 510
Forearm blood flow, 277P
Formoterol, 265P, 654P
Formulary, 551
Formulation, 257
Fractionated ifosfamide, 179
Free radical, 15
Friedrich's ataxia, 107
Frusemide, 522, 652P, 743

GI bleeding, 253
Gabapentin, 531
Galanthamine, 671P
Ganglion blockade, 225
Gastrointestinal, 387
Gender, 632, 660P, 662P
Gene therapy, 683
Genetic polymorphism, 713
Genetic screening, 683
Genetics, 21, 107, 127
Gliotoxin, 119
Glucocorticoids, 659P
Glucose, 415
Gludopa, 650P
γ-L-glutamyl-5-hydroxy-L-tryptophan, 365
γ-L-glutamyl-L-tryptophan, 29
Goals of treatment, 29
Good clinical practice guidelines, 63
Grapefruit juice, 662P
Guthrie cards, 677P

HIV, 278P, 279P, 671P, 672P
Haemodynamic, 261P
Haemolysis, 737
Haemorrhage, 729
Headache, 475
Heart, 107
Helicobacter pylori, 119
Heterocyclic amines, 91
Histamine, 629
Hospital, 551
Hospital admission, 319
Human, 632
Human atrium, 217
Human coronary artery, 431
Human duodenum, 387
Human liver, 81, 390
Human microsomes, 157
Humans, 729
Hydroxyl radical, 451
Hydroxylamine, 347
5-HT_{1D}-receptor agonists, 431
5-hydroxytryptamine, 365, 522
5-hydroxytryptophan, 650P
Hypercholesterolaemia, 333
Hypersensitivity, 679P
Hypertension, 37, 107, 507, 615
Hypertrophic cardiomyopathy, 107
Hypochlorous acid, 451
Hypodermoclysis, 325
Hypoglycaemia, 371
Hypoxaemic cor pulmonale, 276P, 261P
Hypoxia, 127

ICG clearance, 499
Ifosfamide, 179
Imidazoline receptors, 37
Immunological analysis, 81
In vitro metabolism, 157
Inflammation, 3
Inflammatory mediators 3
Influenza vaccination, 529
Inhaled drugs, 697
Inhibition, 81, 347, 518
Insulin, 415
Insulin resistance, 53
Interaction, 249, 279P, 465, 642
Interethnic differences, 713
International conference on harmonization, 63
Intranasal, 379
Isoprostane, 15
Itraconazole, 642

Ketoconazole, 270P, 347
Ketoprofen enantiomers, 163
Kidney, 365, 522

Lactate, 333
Lacticodeshydrogenase, 737
Lamivudine, 279P
Lamotrigine, 531, 621
Large artery diameter, 187
Leukotriene B_4, 457
Leukotriene D_4, 171
Levodopa, 650P, 765
Lifestyle measures, 29
Lignocaine, 242
Lipocortin 1, 658P
Lipolysis, 291
Liver blood flow, 499
Liver cirrhosis, 394
Local anaesthetics, 242
Low density lipoproteins, 662P
Low molecular weight heparin, 283
Lymphoblasts, 281P

MST Continus, 645
Macrophage-1 antigen, 457
Magnesium, 629
Malaria, 411, 589, 599
MeIQx, 91
Measurement of blood pressure, 29
Medicine taking, 567
Mefloquine, 411, 415
Melatonin, 678P
Memory, 664P
Mephenytoin, 518, 771
Mephenytoin metabolism, 471
Mercaptopurine, 525
Metabolic ratio, 774
Metabolism, 91, 347
Metamizol, 307
Metformin, 510
Methadone, 670P
Methotrexate, 195
8-methoxypsoralen, 404
Methyldopa, 53
Methyltransferase, 638
Metoprolol, 518
Mevalonic acid, 119
Microdialysis, 765
Microsomes, 390
Miglitol, 503
Minaprine, 491
Mitochondria, 333
Modified sham feeding, 371
Mono(ADP)-ribosyl) transferase, 99
Morbidity and mortality, 29
Morphine, 645, 663P
Multicentre trials, 143
Mutagenicity, 91
Myocardial function, 262P

N-dealkylation, 390
N-demethylation, 260P
NHI drug pricing system, 63
NHI drug tariff, 63
NONMEM, 283, 589
NSAIDs, 253
Nadolol, 279P
Nalmefene, 301
Nasal decongestant, 657P
National health insurance, 63
Nefazodone, 573
Neonates, 779
Neurological function, 415
Neuropeptides, 3
Neutrophil leucocytes, 99
Neutrophils, 457
New drug application, 63
Nicergoline, 707
Nitric oxide, 263P, 650P, 657P, 651P, 652P, 670P
Non-linear red blood cell partitioning, 605
Non-steroidal anti-inflammatory drugs, 475
Noradrenaline, 217
Nucleoside analogue drugs, 672P
Nucleoside transport inhibitor, 605

Ocular safety, 213
Omeprazole, 157, 213
Omeprazole sulphone, 157
Oncogenes, 43
Opioid antagonists, 301
Oral, 379
Oral contraceptive, 264P
Oramorph SR, 645
Ototoxicity, 233
Oxcarbamazepine, 531
Oxidation polymorphisms, 771
Oxidative stress, 451
Oxycodone, 747
Oxygen radicals, 737
Oxygen therapy, 276P

P. falciparum, 589
Paediatric patients, 319
Paediatrics, 653P
Pancreatic polypeptide, 371
Pantoprazole, 249
Paracetamol, 15
Parameter estimation, 283
Parkinson's disease, 765
Parkinsonism, 667P, 668P
Paroxetine, 757
Patient knowledge, 253
Peak concentration, 242
Peptides, 81
Performance, 664P
Peripheral vascular disease, 782
Pethidine, 307
PhIP, 91
Pharmacodynamic, 675P
Pharmacodynamic parameters, 355
Pharmacodynamics, 379, 599, 605, 675P
Pharmacoeconomics, 271P
Pharmacogenetics, 545, 683
Pharmacokinetic, 675P
Pharmacokinetics, 147, 163, 179, 195, 201, 207, 242, 246, 267P, 268P, 301, 325, 339, 355, 379, 443, 510, 513, 573, 583, 589, 605, 615, 632, 642, 645, 662P, 668P, 670P, 676P, 697, 765, 779, 789
Pharmacy and therapeutics committees, 551
Phenacetin, 673P
Phenotype, 573
Phenytoin, 246, 774
Phosphorylation, 278P
Picotamide, 782
Placebo, 307
Plasma catecholamines, 225
Plasma renin activity, 729
Poisoning, 266P
Polymorphism, 638
Population, 589
Postanaesthetic shivering, 307
Postmarketing surveillance, 559
Powder aerosol, 171
Pramipexole, 660P
Pravastatin, 187
Prazosin, 236
Prednisolone, 654P, 659P
Pregnancy, 651P, 677P
Product monographs, 653P
Proguanil, 589, 771
Propranolol, 339, 390
Prostaglandin, 15
Protein structure, 81
Proteinurea, 615
Proton pump inhibitor, 249
Pseudoephedrine, 665P
Pseudomonas aeruginosa, 119
Psychomotor performance, 239
Pulse, 225
Pulsed Doppler, 187
Pupillary light reflex, 236, 269P

QT interval, 399, 400
QTc interval, 583
Quality of life, 665P

Racial differences, 339
Radioreceptor assay, 147
Randomized trial, 483
Ranitidine, 201, 207
Rat strains, 127
Raynaud's phenomenon, 650P
Reactive metabolites, 655P
Reboxetine, 239
Recombinant human erythropoetin, 355
Recovery, 307
Red blood cell occupancy, 605
Regional anaesthesia, 242
Renal failure, 615
Renal impairment, 163
Renal sodium excretion, 365
Renin, 652P
Reperfusion, 15
Rheumatoid arthritis, 195
Rising dose design, 283
Risperidone, 273P
Ritonovir, 787
Ropinirole, 668P

SAP, 119
Safety, 491, 559
Salbutamol, 257, 658P
Saliva, 635
Salmeterol, 271P
Schizophrenia, 271P, 272P, 273P, 274P, 665P
Secondary prevention, 782
Seizures, 779
Self-medication, 475
Seminal fluid, 678P
Sertraline, 394, 757
Sildenafil, 267P, 268P
Simvastatin, 483
Sleep, 273P
Sleep assessment, 483
Smoking, 15
(±)-sotalol, 583
(+)-sotalol, 583
(−)-sotalol, 583
Source data verification, 559
Spontaneous adverse reaction reports, 757
Statins, 333
Stereoselectivity, 163
Steroid, 119
Stroke, 681
Stroop colour word interference test, 274P
Subcutaneous, 355
Sulphamethazine, 266P
Sulphamethoxazole, 270P, 347
Sulphasalazine, 195
Sulphate, 119
Sulphonamide, 679P
Sulpiride, 271P, 655P
Suppressor genes, 43
Surveillance, 407
Survey, 567
Sympathetic reflex, 236
Systemic effects, 503
Systolic time intervals, 491
T cell proliferation, 656P
T-lymphocytes 3
Target organ damage, 29
Targeted therapy, 683
Taste, 313
Taste disturbance, 559
Terbinafine, 313, 559
Terfenadine, 662P
Testosterone, 673P
Theophylline, 729
Thermal stress, 260P
Thermogenesis, 291
Thioguanine nucleotides, 525
Thiopurine, 638
Thioridazine, 265P
Threshold for treatment?, 29
Thrombolysis, 681
Thyrotrophin releasing hormone, 225
Tiagabine, 531
Timolol, 217
Tolbutamide, 673P, 675P, 774
Tolerability, 676P
Topiramate, 531
Toxicity, 347, 407
Transcription factors 3
Transgenic, 107
Transgenic mouse, 43
Transnasal, 513
Trapidil, 443
Trial, 307
Triazolam, 465
Turkish population, 771

Ubiquinone, 333
Unwanted effects, 491
Uraemia, 269P
Urinary cAMP, 729
Urinary incontinence, 507

Vagus, 371
Vascular tone, 263P, 651P
Vasoactive factors, 127
Vasoconstriction, 187
Vasopressin, 678P
Venoconstriction, 279P
Vigabatrin, 531, 779
Vitamin C, 281P
Vitamin E, 737

Warfarin, 675P
Whites, 339
Wisconsin card sorting test, 275P
Withdrawal reactions, 757

Yellow cards, 423

Zidovudine, 279P, 671P
Zimbabwean, 713
Zolpidem, 664P
Zonisamide, 531
Zopiclone, 664P